The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Haploidentical versus MMUD transplant following treosulfan-based conditioning in AML in CR1
Daniele Avenoso, MD, University of Brescia, Brescia, Italy, discusses the results of a study comparing haploidentical and mismatched unrelated donor (MMUD) transplant following treosulfan-based conditioning in acute myeloid leukemia (AML) in first complete remission (CR1). Dr Avenoso highlights that the study found comparable leukemia-free survival and overall survival rates in patients receiving transplants from these two donor sources. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So one of our questions and our dilemma is should we go to transplant as soon as possible or should we wait for an unrelated donor? With this study I wanted to address this question. Basically, I wanted to analyze the transplant outcomes for patients undergoing transplantation either from haploidentical donors or mismatched unrelated donors after treosulfan-based conditioning regimen with PTCT as backbone of GVHD prophylaxis...
So one of our questions and our dilemma is should we go to transplant as soon as possible or should we wait for an unrelated donor? With this study I wanted to address this question. Basically, I wanted to analyze the transplant outcomes for patients undergoing transplantation either from haploidentical donors or mismatched unrelated donors after treosulfan-based conditioning regimen with PTCT as backbone of GVHD prophylaxis. The results are encouraging and interesting because both leukemia-free survival and overall survival are similar for patients receiving transplant from haploidentical donors and mismatched unrelated donors. These results are telling us that a prompt allogeneic hematopoietic stem cell transplant is as safe and effective as a transplant from a matched unrelated donor that takes more time in terms of logistics. Therefore, we can suggest that the first donor available in a context of the treosulfan-based transplant together with PTCy can offer an encouraging overall survival and leukemia-free survival in AML in first remission.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
MEDAC, Sanofi, Jazz Pharma, Therakos, Alexion.
